Biovista Inc. announces positive efficacy results in a pre-clinical trial of BVA-101 for Multiple Sclerosis

April 2, 2009Press Releases

CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ — Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned in MS and is aimed at neuroprotection, was shown to have both efficacy in … Read More

Cempra Pharmaceuticals and Biovista Inc. enter agreement for macrolide CT design support

September 30, 2008Press Releases

CHAPEL HILL, N.C. and CHARLOTTESVILLE, Va.–(Business Wire)–Cempra Pharmaceuticals, Inc., and Biovista, Inc., announced today that they have entered into a research agreement to systematically identify and profile adverse event associations for members of the macrolide drug class. The data generated will be used to better understand the unique benefit/risk characteristics of this important group of … Read More

Biovista licenses to Upstate Inc. its Journal Research Analyst tool

September 22, 2003Press Releases

ATHENS, Greece and CHARLOTTESVILLE, Va., Sept. 22 /PRNewswire/ Biovista announced today the licensing of its Journal Research Analyst™ market intelligence tool by Upstate, one of the leading suppliers of cell signaling reagents and kinase screening services in the life sciences industry. Journal Research Analyst™ (JRA) enables the rapid and quantitative identification of the use and … Read More